Inozyme Pharma, Inc. (INZY)
Jul 1, 2025 - INZY was delisted (reason: acquired by BMRN)
4.000
0.00 (0.00%)
Inactive · Last trade price
on Jun 30, 2025
Inozyme Pharma Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Inozyme Pharma stock had an average target of 15.22, with a low estimate of 4 and a high estimate of 30.
Price Target: $15.22 (+280.5%)
Analyst Consensus: Buy
* Price targets were last updated on May 16, 2025.
Analyst Ratings
The average analyst rating for Inozyme Pharma stock from 9 stock analysts was "Buy". This means that analysts believed this stock was likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 4 | 3 | 3 |
| Buy | 3 | 3 | 5 | 5 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 10 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $4 | Buy → Hold | Downgrades | $4 | n/a | May 16, 2025 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $15 → $4 | Strong Buy → Hold | Downgrades | $15 → $4 | n/a | May 16, 2025 |
| Needham | Needham | Strong Buy → Hold Downgrades $12 | Strong Buy → Hold | Downgrades | $12 | +200.00% | May 16, 2025 |
| Needham | Needham | Strong Buy Maintains $15 → $12 | Strong Buy | Maintains | $15 → $12 | +200.00% | May 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +300.00% | Apr 10, 2025 |
Financial Forecast
Revenue This Year
n/a
from 191.73M
Revenue Next Year
n/a
EPS This Year
-1.46
from -1.62
EPS Next Year
-1.17
from -1.46
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 7.8M | 144.7M | ||
| Avg | n/a | 1.1M | 36.5M | ||
| Low | n/a | n/a | 2.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 13,300.9% | ||
| Avg | - | - | 3,284.1% | ||
| Low | - | - | 172.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.22 | -0.80 | 0.15 |
| Avg | -1.46 | -1.17 | -0.80 |
| Low | -1.61 | -1.47 | -1.76 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.